Stock Events

Stock Events

MindWalk 

€0.85
83
-€0.01-1.16% Tuesday 06:02

Statistics

Day High
0.85
Day Low
0.85
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
39.23M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MarExpected
Q2 2025
Q2 2025
Q3 2025
Q4 2025
-0.06
-0.06
-0.05
-0.04
Expected EPS
-0.039667295
Actual EPS
-0.058712

Financials

-123.82%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
31.81MRevenue
-39.39MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TQB0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is a leading biotech company that competes in the development of monoclonal antibodies, a core area of ImmunoPrecise Antibodies' business.
Adaptive Biotechnologies
ADPT
Mkt Cap2.64B
Adaptive Biotechnologies focuses on the immune-driven discovery and development of antibodies, directly competing with IPA's antibody discovery services.
AbCellera Biologics
ABCL
Mkt Cap1.66B
AbCellera Biologics uses a technology platform for antibody discovery that rivals ImmunoPrecise Antibodies' technologies and services.
Moderna
MRNA
Mkt Cap10.61B
Moderna, known for its mRNA technology, is expanding into antibody discovery and therapeutics, positioning it as a competitor in the biotech space.
Novavax
NVAX
Mkt Cap1.36B
Novavax, primarily focused on vaccine development, competes with IPA in the broader immunotherapy and antibody development market.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE, while known for its COVID-19 vaccine, also engages in antibody research and development, making it a competitor.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company has a strong portfolio in antibody therapeutics, directly competing with IPA in the pharmaceutical and biotech market.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biopharmaceutical company with a focus on human therapeutics, including antibodies, competing in similar therapeutic areas as IPA.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the discovery, development, and commercialization of therapeutics, including antibodies, in areas that overlap with IPA's interests.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company with a broad range of therapeutic products, including antibodies, competing across several of the same domains as ImmunoPrecise Antibodies.

About

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
Show more...
CEO
ISIN
CA6026871054
WKN
000A41GYL

Listings

XNAS
US
HYFT
F
DE
TQB0.F
BOATS
BOATS
HYFT.BOATS

0 Comments

Share your thoughts

FAQ

What is MindWalk stock price today?▼
The current price of TQB0.F is €0.85 EUR — it has decreased by -1.16% in the past 24 hours. Watch MindWalk stock price performance more closely on the chart.
What is MindWalk stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MindWalk stocks are traded under the ticker TQB0.F.
What is MindWalk market cap?▼
Today MindWalk has the market capitalization of 39.23M
When is the next MindWalk earnings date?▼
MindWalk is going to release the next earnings report on July 23, 2026.
What were MindWalk earnings last quarter?▼
TQB0.F earnings for the last quarter are -0.05 EUR per share, whereas the estimation was -0.03 EUR resulting in a -48.01% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is MindWalk revenue for the last year?▼
MindWalk revenue for the last year amounts to 31.81M EUR.
What is MindWalk net income for the last year?▼
TQB0.F net income for the last year is -39.39M EUR.
When did MindWalk complete a stock split?▼
The last stock split for MindWalk was on November 23, 2020 with a ratio of 1:5.